

Are antidepressants effective in primary care?

Department of General Practice and Primary Health Care University of Auckland

Professor Bruce Arroll



eLearning Podcast Gems Webinars Events Symposium by Category

Sign in

Register

Search

Continuing Professional Development

general practice and primary health care



Red whale



The Ottawa SAH rule

The Ottawa SAH rule was developed to pick up anyone who could possibly have a SAH (highly sensitive test), but may actually have a different diagnosis (low specificity). It was developed for use in an A&E setting, not in primary care. A positive score on the Ottawa SAH rule may add weighting to our referral (use as a rule in test). We should NOT be reassured by a score of 0; if we have clinical suspicion of a SAH we should always refer.

Red whale



Ottawa subarachnoid haemorrhage rule

- Use for those over 15y presenting with new, severe, non-traumatic headache reaching maximum intensity within 1h and NO neurological deficit.
- Do NOT use for patients with new neurologic deficits, previous aneurysms, SAH, brain tumours, or history of recurrent headaches (≥3 episodes over the course of ≥6m).
- Score 1 for each feature. Investigate if score ≥1.

Sensitivity 100% (Cl 97–100) and specificity 15% (Cl 14–17) when tested on over 2000 adults presenting to A&E departments in Canada with a headache peaking in less than 1h and no neurological deficits (JAMA 2013;310:1248).

Age ≥40y

Neck pain or stiffness

Witnessed loss of consciousness

Onset during exertion

Thunderclap headache (instantly peaking pain)

Limited neck flexion on examination

year 2000 Manurewa

- many pts on antidepressant
- mainly ssri
- majority still depressed
- SR antidepressants vs placebo
- cochrane review
- repeated 2016
 - Arroll et al j prim health care 2016;8:325-34

NNT

- amitriptyline 5
- sertraline 6
- escitalopram 8.5

drugs only work for severe?

Level of depression	Active drug effect	Placebo
Mild moderate	6%	47%
Severe	9%	47%
Very severe	25%	30%


- Fournier JC, Jama 2010;303(1):47-53
- Most effect is placebo

severity

- moderate 6 papers
- severe 13 papers
- very severe 3 papers


- 27% moderate
- 73% severe or very
- PC sees about 10% severe

publication bias



Kirsch I, et al PLoS medicine 2008;5(2):e45.

publication bias



- Arroll B, et al J prim health care 2016;8(4):325-34.

who has MDD severe

- multiple city practices 2240 pts
- GP says 399 (18%) major/minor dep
- of 399 232 have MDD (12%)
- of those 80 (3.6%) mod-severe dep
 - PHQ 9 score ≥ 15 (out of 27)

stuck - trans-diagnostic

The scans don't match

```
major depressive disorder panic disorder

PTSD

Jama 2018;75(2): 201-9
```

dsm 6 – trans-diagnostic

anxiety, fearfulness, depression

will become

a bottom up network disorder

the value of a diagnosis

- in primary care overlap dep/anxiety
- move to common mental disorder

- or mixed anxiety/depression
- ACT use transdiagnostic "stuck"

the value of a diagnosis

- treatments the same
- ? time on diagnosis vs therapy

treat depress/distress

60% of patients resolve in one year¹

- PHQ 9 scores are lower at next visit
 - having had a discussion of symptoms
 - -the "doctor as the drug" (Balint)
 - reframing-normalisation-hope-support
 - regression to mean

- 1 Chin WY et al Fam pract 2015;32:288

treat depress/distress

- NICE 2016
- lower levels of severity
- non-drug therapies
 - CBT and computerised CBT
 - exercise (incl. yoga and stretching)
 - behavioural activation
 - problem solving
 - -sleep hygiene

drugs at first visit

- absence of evidence
- majority PC patients mild-moderate
- many severe will become mild/mod
- try non drug first
- drug only if
 - past mod-severe depression persisting
 - lower symptoms duration 2 years

when do drugs work

- severe end of depression
- how to recognise this
- a persisting high PHQ-9
- ? patient not getting better
- previous episodes
- 12% of kiwis on antidepressants

life constriction

 life constriction accompanies mental health issues

- expand life
 - get back in the river of life

if cannot expand? medication

work love play- answer here

brucearroll.com - all free work 3/10* love friends 8/10 love intimates 1/10 love family 8/10 play 3/10* spiritual Al Anon meetings interventions call out



harms of drugs

- medicalise the condition
- placebo effect 8 to 3 times greater
- patient credits drug not themselves
- risk of adverse effects
- risk of overdose
- ? increase suicidality in teenagers
- difficult to stop- withdrawal sx¹

Warner C et al. Am Fam phys 2006;74:449

what else helps

- nurse phone call 1 to 2 phone calls/week in first 2 weeks of enrolment, decreasing to week 16
- NNT = 5 at 6 months
 - Hunkeler E et al. Arch fam med 2000;9:700

take home

- first visit measure distress PHQ?
- work love play
- expand life
- non drug therapies
- if symptoms persist consider medication
- 4-6 weeks check if responding if not try another? Class

the end

PHQ 9 and depression

Severity N= 2642	Depressed DSM 4 % all patients	Not depressed DSM 4
Mild 5 - 9	156 (6%)	402 (15.2%)
Moderate 10 - 14	102 (3.9%)	102 (3.9%)
Mod-severe 15-19	66 (2.5%)	24 (0.9%)
Severe 20-27	37 (1.4%)	10 (0.4%)

• a high PHQ 9 ≠ depression

	Placebo	Antidepress	ant		Risk Ratio		Risk Ratio
Study or Subgroup	Events Tot	al Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Thomson 1982	13 2	1 5	15	5.0%	1.86 [0.84, 4.09]	1982	 •
Hollyman 1988	53 (7 39	74	23.3%	1.50 [1.17, 1.92]	1988	-
Doogan 1994	48 9	6 40	90	19.3%	1.13 [0.83, 1.53]	1994	+
Mynors-Wallis 1995	16 3	1 8	30	6.4%	1.94 [0.98, 3.84]	1995	
Lecrubier 1997	44 (7 44	67	23.5%	1.00 [0.78, 1.28]	1997	+
Phillip 1999	70 10	5 29	46	22.5%	1.06 [0.82, 1.37]	1999	+
Total (95% CI)	38	7	322	100.0%	1.23 [1.01, 1.48]		•
Total events	244	165					
Heterogeneity: Tau ² = 0.02; Chi ² = 9.47, df = 5 (P = 0.09); I ² = 47%							
Test for overall effect: 2	Z= 2.10 (P = 0	.04)					0.01 0.1 1 10 100 placebo antidepressant

	SSR	ll .	Place	bo		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Doogan 1994	50	83	40	90	12.8%	1.36 [1.01, 1.81]	1994	-
Malt 1999	74	122	60	129	19.4%	1.30 [1.03, 1.65]	1999	 -
Wade 2002	89	161	68	161	20.4%	1.31 [1.04, 1.64]	2002	-
Lepola (Citalo) 2003	80	152	34	70	13.2%	1.08 [0.82, 1.44]	2003	+
Lepola (Escit) 2003	93	146	33	69	14.1%	1.33 [1.01, 1.75]	2003	-
Bjerkenstedt 2005	15	54	4	54	1.0%	3.75 [1.33, 10.57]	2005	
Gastpar 2006	71	127	51	130	15.3%	1.43 [1.09, 1.86]	2006	
Hegerl 2010	22	48	15	56	3.8%	1.71 [1.01, 2.91]	2010	-
Total (95% CI)		893		759	100.0%	1.33 [1.20, 1.48]		•
Total events	494		305					
Heterogeneity: Tau² = 0.00; Chi² = 7.12, df = 7 (P = 0.42); l² = 2%							0.01 0.1 1 10 100	
Test for overall effect: Z	= 5.34 (F	° < 0.00	001)					Favours [Placebo] Favours [SSRI]

the depression diagnosis

- a good rule out is a "no" to 2Q
- have you felt depressed down or hopeless most of past month
- have you lost interest, pleasure in all or most activities past month

- high sensitivity so a good rule out
 - Arroll et al BMJ 2005;331:884